CRDF News and Press, Cardiff Oncology Inc. From 06/28/21

Cardiff Oncology (CRDF) was added to the Russell 2000, Russell 3000 and the Russell Microcap indexes as part of the 2021 Russell indexes annual reconstitution, effective June 28 after the U.S. market opens. The company said membership in the U.S. all-cap Russell 3000 Index...

Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes PR Newswire SAN DIEGO , June 28, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage biotechnology company developing onvansertib to treat cancers w...

CRDF fell on January data from CRC trial. However, the market had reacted more positively to its CRPC data. The huge fall doesn't seem warranted. For further details see: Cardiff Oncology: Current Slump Doesn't Look Right

Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors - Mani Mohindru, Ph.D., Chief Executive Officer of Novasenta, an early-stage biopharmaceutical company, has deep expertise in all phases of drug development, finance, strategy and...

Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer - Trial represents a key component of onvansertib's KRAS-targeted clinical programs and is designed to leverage the synergy of onvanserti...

Gainers: Annovis Bio (ANVS) +250%.Jiuzi Holdings (JZXN) +27%.Longeveron (LGVN) +25%.Wah Fu Education (WAFU) +22%.Mesa Royalty Trust (MTR) +20%.Gracell Biotechnologies (GRCL) +20%.Obalon Therapeutics (OBLN) +16%.Yalla Group (YALA) +16%.VOC Energy Trust (VOC) +12%.Cyclo Therapeut...

Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference PR Newswire SAN DIEGO , May 20, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the...

Cardiff Oncology (CRDF): Q1 GAAP EPS of -$0.14 beats by $0.01.Revenue of $0.07M (flat Y/Y) misses by $0.08M.Press Release For further details see: Cardiff Oncology EPS beats by $0.01, misses on revenue

Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights PR Newswire SAN DIEGO , May 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the...

The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...